Compass Therapeutics has announced top-line data from its ongoing COMPANION-002 trial investigating its antibody-based therapeutic for biliary tract cancer (BTC), tovecimig.

Rhythm Pharmaceuticals (RYTM) announced topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 ...

"Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC" was originally created and published by Clinical ...

The trial did not meet its primary endpoint of mean change in best corrected visual acuity from baseline to week 52. In wet AMD patients with minimally classic and occult lesions, participants ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in combination with 2 mg aflibercept did not meet its primary endpoint ...

This analysis did not demonstrate statistically significant superiority in overall survival, the primary endpoint. However, although the trial was not powered to determine non-inferiority ...

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives. But the biotech brushed off the setback, highlighting other secondary ...

In the main trial, BP fell by 30.2±18.5/16.6±10.1 ... which was one of the primary endpoint components. For the overall primary endpoint, there was a 13% overall relative risk reduction for ...

(RTTNews) - Axsome Therapeutics, Inc. (AXSM), Tuesday announced that the FOCUS Phase 3 trial of solriamfetol ... The study achieved the primary endpoint by demonstrating a statistically ...

XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne- - Over 30 million acne patients seek ...